The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Early Depressive Symptoms in Cancer Patients Receiving Interleukin 2 and/or Interferon Alfa-2b Therapy
Abstract
PURPOSE: Depressive symptomatology is frequently associated with interleukin (IL)-2 and interferon alfa-2b (INFα-2b) therapy in cancer patients. The objective of the present study was to evaluate the depressive and anxiety symptoms induced by IL-2 and/or INFα-2b in cancer patients during the first days of cytokine immunotherapy. PATIENTS AND METHODS: The study included 48 patients with renal cell carcinoma or melanoma. Patients were treated either with subcutaneous IL-2, alone (n = 20) or in combination with INFα-2b (n = 6); or with INFα-2b alone, administered subcutaneously at a low dose (n = 8) or intravenously at a high dose (n = 14). Depressive symptoms were evaluated using the Montgomery and Asberg Depression Rating Scale (MADRS), and anxiety symptoms were evaluated using the Covi scale. Evaluations were performed just before initiation of treatment (day 1) and on days 3 and 5 of treatment. RESULTS: Patients treated with IL-2 alone or in association with INFα-2b had significantly higher MADRS scores after 5 days of cytokine therapy, and patients who received both cytokines had increased scores on day 3. In contrast, patients treated with INFα-2b alone did not have varying MADRS scores during the course of treatment. Cytokine therapy had no effect on anxiety, except in patients treated with IL-2 in combination with INFα-2b. In these patients, the enhancement in anxiety scores that was observed on day 5 was mainly attributable to increased somatic complaints. CONCLUSION: IL-2 and INFα-2b have differential effects on mood, and IL-2 therapy induces depressive symptoms early in treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161501 · Cited by 2,735
Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.7 · Cited by 2,094
Fever: Role of Pyrogens and Cryogens
Kluger, M. J. (1991) · Physiological Reviews · doi:10.1152/physrev.1991.71.1.93 · Cited by 1,215
Negrier, S., Escudier, B., Lasset, C., Douillard, J.-Y., Savary, J., Chevreau, C., Ravaud, A., Mercatello, A., Peny, J., Mousseau, M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381805 · Cited by 967
Self-citationCytokines and the nervous system II: actions and mechanisms of action
Rothwell, N. J., & Hopkins, S. J. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)93890-a · Cited by 923
Cytokines and the nervous system I: expression and recognition
Hopkins, S. J., & Rothwell, N. J. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)80029-2 · Cited by 751
Endotoxin produces a depressive-like episode in rats
Yirmiya, R. (1996) · Brain Research · doi:10.1016/0006-8993(95)01415-2 · Cited by 604
The Neuropsychiatric Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells
DENICOFF, K. D., RUBINOW, D. R., PAPA, M. Z., SIMPSON, C., SEIPP, C. A., LOTZE, M. T., CHANG, A. E., ROSENSTEIN, D., & ROSENBERG, S. A. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-293 · Cited by 455
Psychiatric Complications of Long-term Interferon Alfa Therapy
Renault, P. F. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370090055011 · Cited by 413
Immunoregulators in the nervous system
Plata-Salamán, C. R. (1991) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80001-6 · Cited by 380
Mood and cognitive side effects of interferon-alpha therapy.
Valentine, A. D., Meyers, C. A., Kling, M. A., Richelson, E., & Hauser, P. (1998) · PubMed · Cited by 312
Immune-neuroendocrine interactions
Besedovsky, H. O., del Rey, A. E., & Sorkin, E. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.2.750 · Cited by 307
Cytokines and Sickness Behavior
DANTZER, R., BLUTHÉ, R., LAYÉ, S., BRET‐DIBAT, J., PARNET, P., & KELLEY, K. W. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb09597.x · Cited by 288
Self-citationCapuron, L., & Ravaud, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401716 · Cited by 169
Self-citationSleijfer, D. T., Janssen, R. A., Buter, J., de Vries, E. G., Willemse, P. H., & Mulder, N. H. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1119 · Cited by 169
Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia
Pavol, M. A., Meyers, C. A., Rexer, J. L., Valentine, A. D., Mattis, P. J., & Talpaz, M. (1995) · Neurology · doi:10.1212/wnl.45.5.947 · Cited by 160
Morikawa, O., Sakai, N., Obara, H., & Saito, N. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00187-3 · Cited by 160
Repeated interferon-α administration inhibits dopaminergic neural activity in the mouse brain
Shuto, H., Kataoka, Y., Horikawa, T., Fujihara, N., & Oishi, R. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01371-6 · Cited by 151
Effect of Interferon-α Treatment of Chronic Hepatitis C on Health-Related Quality of Life
Hunt, C. M., Dominitz, J. A., Phillips‐Bute, B. G., Waters, B., Blasi, U., & Williams, D. M. (1997) · Digestive Diseases and Sciences · doi:10.1023/a:1018852309885 · Cited by 141
Sarro, G. D., Masuda, Y., Ascioti, C., Audino, M. G., & Nisticò, G. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90057-x · Cited by 117
Modulation of hippocampal acetylcholine release: a potent central action of interleukin-2
Hanisch, U., Seto, D., & Quirion, R. (1993) · Journal of Neuroscience · doi:10.1523/jneurosci.13-08-03368.1993 · Cited by 103
Anisman, H., Kokkinidis, L., & Merali, Z. (1996) · Brain Research · doi:10.1016/0006-8993(96)00460-x · Cited by 97
Buckingham, J. C., Loxley, H. D., Christian, H., & Philip, J. G. (1996) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)02127-2 · Cited by 89
Symptomatic volunteers in multicenter drug trials
Covi, L., Lipman, R. S., McNair, D. M., & Czerlinsky, T. (1979) · Progress in Neuro-Psychopharmacology · doi:10.1016/0364-7722(79)90006-7 · Cited by 85
Esophagitis and Gastroduodenal Disorders Associated With Diabetic Gastroparesis
Parkman, H. P., & Schwartz, S. S. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370080113021 · Cited by 83
Anisman, H., Kokkinidis, L., Borowski, T. B., & Merali, Z. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01114-1 · Cited by 82
The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical trial
Walker, L., Walker, M. B., Heys, S. D., Lolley, J., Wesnes, K. A., & Eremin, O. (1997) · Psycho-Oncology · doi:10.1002/(sici)1099-1611(199712)6:4<290::aid-pon283>3.0.co;2-g · Cited by 69
RABER, J., KOOB, G. F., & BLOOM, F. E. (1997) · Neurochemistry International · doi:10.1016/s0197-0186(96)00082-4 · Cited by 50
Repeated Injections of Interferon-α A/D in Balb/c Mice: Behavioral Effects
Dunn, A. L., & Crnic, L. S. (1993) · Brain Behavior and Immunity · doi:10.1006/brbi.1993.1011 · Cited by 50
Walker, L. G., Wesnes, K. A., Keys, S., Walker, M. B., Lolley, J., & Eremin, O. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00300-0 · Cited by 43
Diagnostic dilemmas presented by patients with anxiety and depression
Goldberg, R. J. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80375-1 · Cited by 27
Ravaud, A., Bédane, C., Geoffrois, L., Lesimple, T., & Delaunay, M. M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690595 · Cited by 23
Self-citationProstaglandins do not mediate interferon-α effects on mouse behavior
Crnic, L. S., & Segall, M. A. (1992) · Physiology & Behavior · doi:10.1016/0031-9384(92)90152-r · Cited by 18
Neuropsychiatric symptoms during treatment with interleukin-2 and interferon-α
Fenner, M. H., Hänninen, E. L., Kirchner, H., POLIWODA, H., & Atzpodien, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)90172-d · Cited by 13
Research works printed but not linked: 2
- 10.1016/S1040-8428(99)00005-0 · doi:10.1016/s1040-8428(99)00005-0
- 10.1002/pon.2960010208 · doi:10.1002/pon.2960010208
Cited by
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Self-citationCancer-related fatigue—mechanisms, risk factors, and treatments
Bower, J. E. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.127 · Cited by 1,666
Cytokine-induced sickness behaviour: mechanisms and implications
Konsman, J. P., Parnet, P., & Dantzer, R. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02088-9 · Cited by 999
Self-citationTaylor, S. E. (2012) · The Oxford Handbook of Health Psychology · doi:10.1093/oxfordhb/9780195342819.013.0009 · Cited by 993
Reciprocal regulation of the neural and innate immune systems
Irwin, M. R., & Cole, S. W. (2011) · Nature Reviews Immunology · doi:10.1038/nri3042 · Cited by 910
Metadata
- Authors
- Capuron, L., Ravaud, A., & Dantzer, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-05-10
- Volume
- 18
- Issue
- 10
- Pages
- 2143-2151
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2101652715
- Cited by
- 294
- References
- 35
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.